ETT URVAL AV PUBLIKATIONER
En stark vetenskaplig grund kring de potentiella fördelarna med arfolitixorin (Modufolin®), har byggts upp med omfattande forskning. Nedan följer ett urval av tillgängliga resultat:
- Carlsson, Göran, et al. ”ISO-CC-005; a phase I/II study of arfolitixorin ([6R]-5,10-MTHF) in combination with 5-fluorouracil (5-FU), irinotecan and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer”. Poster at ESMO 2018 >>
- Gustavsson, Bengt, et al. ”Folate gene prediction of treatment response to 5-FU and leucovorin in metastasizing colorectal cancer”. Poster at ASCO 2018 >>
- Gustavsson, Bengt, et al. ”A review of the evolution of systemic chemotherapy in the management of colorectal cancer”. Clinical colorectal cancer 14.1 (2015): 1-10 >>
- Danenberg, Peter V., et al. ”Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action”. Critical Reviews in Oncology/Hematology 106 (2016): 118-131 >>
- Taflin, Helena, et al. ”Folate levels measured by LC–MS/MS in patients with colorectal cancer treated with different leucovorin dosages”. Cancer chemotherapy and pharmacology 74.6 (2014): 1167-1174 >>
